FLOWER MOUND, Texas, Aug. 12 /PRNewswire-FirstCall/ -- American HealthChoice, Inc. (Pink Sheets: AMHI), http://www.americanhealthchoice.com, a medical services company with medical clinics in Texas and Tennessee, is pleased to announce the launch of the U.S. FDA approved OmniBody Scan, an infrared thermal imaging camera that will be able to detect patterns of abnormality within the human body. In conjunction with existing technologies, the OmniBody Scan (http://www.omnibodyscan.com) will be able to identify problems early enough for prevention and treatment.
According to Pat McGlashan, President of RehabCo, a division of AMHI, "Our initial focus will be the worldwide problem of breast cancer. The dilemma that all women have is that having X-rays to detect breast cancer may cause breast cancer. The OmniBody Scan is a non-invasive tool that will have no harmful side effects. The earlier that breast cancer is detected equates to a much higher chance of survival, especially with Inflammatory Breast Cancer (IBC)."
The OmniBody Scan is manufactured specifically for American HealthChoice by a respected infrared imaging manufacturer with years of successful experience in this field. Efforts have begun to solicit resellers to penetrate the U.S. market with both the OmniBody Scan and the Company's adjunct support system of providing high quality "interpretations" of the infrared images.
"We wish to express our sincere thanks to our investors and shareholders for their patience in allowing us to finally introduce the OmniBody Scan with the proper FDA approvals and technology. This is the product that we wanted from the beginning. While it is manufactured by a different company than the original version, it adheres to the highest standards of thermography. It is easy to use and offers a very high grade of technology and quality. This is a great market for American HealthChoice to enter and, while it took longer than anticipated, we have great expectations on the results both short and long term," said Mr. McGlashan.
Five years ago, the U.S. Preventive Services Task Force, an independent panel of experts in primary care and prevention, examined data from numerous clinical trials and estimated that screening mammography every one or two years in women in their 40s resulted in a 15 percent decrease in breast cancer mortality after 14 years of follow-up. But, analyses also made note of the potential harm of screening, including radiation exposure, procedure- associated pain, false-positive results, over-diagnosis and potentially unnecessary treatment.
"The Company continues it litigation against Texas Infrared, the original manufacturer, in the matter of the OmniBody Scan and we anticipate an outcome favorable to American HealthChoice," said Dr. John W. Stucki, CEO.
The OmniBody Scan, a non-invasive technology with absolutely no harmful side effects, is available today. For additional information or to become an authorized reseller, please contact Pat McGlashan at 817-837-8000, ext. 222, or email@example.com.
Safe Harbor Statement: The statements in this release that relate to
future plans, expectations, events, performance, and the like are forward-
looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and the Securities Exchange Act of 1934. Actual results
or events could differ materially from those described in the
forward-looking statements due to a variety of factors, including those set
forth in the Company's report on Form 10-KSB filed with the Securities and
Dr. J.W. Stucki, CEO
American HealthChoice, Inc.
E & E Communications
|SOURCE American HealthChoice, Inc.|
Copyright©2008 PR Newswire.
All rights reserved